মঙ্গলবার, ১ মে, ২০১২

Study: Heavy teens have trouble managing diabetes

Judith Garcia, 19, fills a syringe as she prepares to give herself an injection of insulin at her home in the Los Angeles suburb of Commerce, Calif., Sunday, April 29, 2012. A major study, released Sunday, tested several ways to manage blood sugar in teens newly diagnosed with diabetes and found that nearly half of them failed within a few years and 1 in 5 suffered serious complications. Garcia still struggles to manage her diabetes with metformin and insulin years after taking part in the study at Children's Hospital Los Angeles. (AP Photo/Reed Saxon)

Judith Garcia, 19, fills a syringe as she prepares to give herself an injection of insulin at her home in the Los Angeles suburb of Commerce, Calif., Sunday, April 29, 2012. A major study, released Sunday, tested several ways to manage blood sugar in teens newly diagnosed with diabetes and found that nearly half of them failed within a few years and 1 in 5 suffered serious complications. Garcia still struggles to manage her diabetes with metformin and insulin years after taking part in the study at Children's Hospital Los Angeles. (AP Photo/Reed Saxon)

Judith Garcia, 19, gives herself an injection of insulin at her home in the Los Angeles suburb of Commerce, Calif., Sunday, April 29, 2012. A major study, released Sunday, tested several ways to manage blood sugar in teens newly diagnosed with diabetes and found that nearly half of them failed within a few years and 1 in 5 suffered serious complications. Garcia still struggles to manage her diabetes with metformin and insulin years after taking part in the study at Children's Hospital Los Angeles. (AP Photo/Reed Saxon)

Judith Garcia, 19, fills a syringe as she prepares to give herself an injection of insulin at her home in the Los Angeles suburb of Commerce, Calif., Sunday, April 29, 2012. A major study, released Sunday, tested several ways to manage blood sugar in teens newly diagnosed with diabetes and found that nearly half of them failed within a few years and 1 in 5 suffered serious complications. Garcia still struggles to manage her diabetes with metformin and insulin years after taking part in the study at Children's Hospital Los Angeles. (AP Photo/Reed Saxon)

Judith Garcia, 19, pinches her abdomen to make a firm place to give herself an injection of insulin at her home in the Los Angeles suburb of Commerce, Calif., Sunday, April 29, 2012. A major study, released Sunday, tested several ways to manage blood sugar in teens newly diagnosed with diabetes and found that nearly half of them failed within a few years and 1 in 5 suffered serious complications. Garcia still struggles to manage her diabetes with metformin and insulin years after taking part in the study at Children's Hospital Los Angeles. (AP Photo/Reed Saxon)

(AP) ? New research sends a stark warning to overweight teens: If you develop diabetes, you'll have a very tough time keeping it under control.

A major study, released Sunday, tested several ways to manage blood sugar in teens newly diagnosed with diabetes and found that nearly half of them failed within a few years and 1 in 5 suffered serious complications. The results spell trouble for a nation facing rising rates of "diabesity" ? Type 2 diabetes brought on by obesity.

The federally funded study is the largest look yet at how to treat diabetes in teens. Earlier studies mostly have been in adults, and most diabetes drugs aren't even approved for youths. The message is clear: Prevention is everything.

"Don't get diabetes in the first place," said Dr. Phil Zeitler of the University of Colorado Denver, one of the study leaders.

A third of American children and teens are overweight or obese. They are at higher risk of developing Type 2 diabetes, in which the body can't make enough insulin or use what it does make to process sugar from food. Until the obesity epidemic, doctors rarely saw children with Type 2 diabetes. The more common kind of diabetes in children is Type 1, which used to be called juvenile diabetes.

Doctors usually start Type 2 treatment with metformin, a pill to lower blood sugar. If it still can't be controlled, other drugs and daily insulin shots may be needed. The longer blood sugar runs rampant, the greater the risk of suffering vision loss, nerve damage, kidney failure, limb amputation ? even heart attacks and strokes.

The goal of the study was simple: What's the best way for teens to keep diabetes in check?

The study involved 699 overweight and obese teens recently diagnosed with diabetes. All had their blood sugar normalized with metformin, then were given one of three treatments to try to maintain that control: metformin alone, metformin plus diet and exercise counseling, or metformin plus a second drug, Avandia.

After nearly four years, half in the metformin group failed to maintain blood sugar control. The odds were a little better for the group that took two drugs but not much different for those in the lifestyle group.

Even so, Zeitler said doctors would not recommend this combination drug therapy because Avandia has been linked to higher risk of heart attacks in adults. Those risks became known after this study had started.

Another study leader from Children's Hospital Los Angeles, Dr. Mitchell Geffner, agreed that Avandia can't be recommended for teens, but said the study makes clear they will need more than metformin to control their disease.

"A single pill or single approach is not going to get the job done," he said.

Among all the teens in the study, 1 in 5 had a serious complication such as very high blood sugar, usually landing them in the hospital.

The results were published online Sunday by the New England Journal of Medicine and presented at a pediatric meeting in Boston. The National Institutes of Health funded the study and drug companies donated the medications.

The "discouraging" results point to the need to create "a healthier 'eat less, move more'" culture to help avoid obesity that contributes to diabetes, Dr. David Allen of the University of Wisconsin School of Medicine and Public Health wrote in an accompanying editorial.

Judith Garcia still struggles to manage her diabetes with metformin and insulin years after taking part in the study at Children's Hospital Los Angeles. She has to remember to watch her diet and set aside time to exercise.

"Trust me, I'm working on it," said the 19-year-old who lives in Commerce, Calif.

Kelsi Amer, a 14-year-old high school freshman from Patriot, Ind., knows how tough it is to keep her blood sugar from skyrocketing. Diagnosed at age 12, she takes metformin and gives herself insulin shots before school and at bedtime.

There are times when she has to miss class because she has to prick her finger to check her blood sugar or go with her mother to Cincinnati Children's Hospital Medical Center for check-ups.

"I try real hard and all of a sudden, I'm back to high blood sugar" levels, said Kelsi, who was not part of the research.

___

Online:

New England Journal of Medicine: http://www.nejm.org

___

Follow Alicia Chang's coverage at http://www.twitter.com/SciWriAlicia

Associated Press

Insulated Picnic Bags gain weight Cape Verde weather Microdermabrasion Machine

Pitcairn Islands Expedition: Best Sunset And Cloud Photos

The Layers Revealed

1? of ?5

As the light changed with the setting sun, once flat white blobs of cloud were teased out into layers of different cloud types and varying distances and elevations.

As the light changed with the setting sun, once flat white blobs of cloud were teased out into layers of different cloud types and varying distances and elevations.

The Layers Revealed

As the light changed with the setting sun, once flat white blobs of cloud were teased out into layers of different cloud types and varying distances and elevations.

More From the Pitcairn Islands Expedition

Top Fish Photos From Pitcairn Island

Photo Gallery: Strange and Beautiful Algae

Photo Gallery: Oeno, the Kingdom of the Groupers

Remnants of a Lost Civilization

Hiking to Christian?s Cave

Rock Climbing for Rock Art

Mike Fay?s Pitcairn Journal

Account of a Typical Morning

Watch Slideshow and Interview With Enric Sala From the Field

Read All Blogs

Also on HuffPost:

Contribute to this Story:

"; var coords = [-5, -72]; // display fb-bubble FloatingPrompt.embed(this, html, undefined, 'top', {fp_intersects:1, timeout_remove:2000,ignore_arrow: true, width:236, add_xy:coords, class_name: 'clear-overlay'}); });

education in Louisiana Charleston Injury Lawyer dog obedience training singing tips for beginners

South Korea opens up cellphone sales, networks wary of the 'free market'

South Korea opens up cellphone sales, networks wary of the 'free market'

South Korea's Communications Commission is wresting control of the domestic cellphone market away from operators. From May 1st, it is opening the handset business open to any vendor, who will sell phones unlocked so consumers can decide their choice of network. The plan is aimed at lowering prices by introducing competition between the retailers -- although some voices in the industry have expressed concerns that the operators will withdraw discounted offers in retaliation. Naturally, the KCC is determined to ensure a better deal for consumers, and is already strong-arming wayward networks into ensuring that doesn't happen.

South Korea opens up cellphone sales, networks wary of the 'free market' originally appeared on Engadget on Mon, 30 Apr 2012 19:28:00 EDT. Please see our terms for use of feeds.

Permalink The Next Web  |  sourceMK  | Email this | Comments

Angela Reston Trinity Caribbean Jumbo Hammock bed bugs burton snowboards

AAA: Inadequate guardrails at NY site where 7 died

This undated photo provided by the family shows Marly Rosario, 3, who died Sunday, April 29, 2012, when seven members of the same family, across three generations, died when their SUV plunged off a highway in to a ravine in the Bronx borough of New York. Police said at a briefing Monday that Maria Gonzalez was driving at 68 mph when the vehicle bumped a concrete barrier on an overpass of the Bronx River Parkway, bounced across three lanes of traffic, jumped across a low concrete barrier and a guardrail, and plunged 59 feet down into the ravine in an unoccupied part of the Bronx Zoo, killing all seven inside, including three children.(AP Photo/Family Photo)

This undated photo provided by the family shows Marly Rosario, 3, who died Sunday, April 29, 2012, when seven members of the same family, across three generations, died when their SUV plunged off a highway in to a ravine in the Bronx borough of New York. Police said at a briefing Monday that Maria Gonzalez was driving at 68 mph when the vehicle bumped a concrete barrier on an overpass of the Bronx River Parkway, bounced across three lanes of traffic, jumped across a low concrete barrier and a guardrail, and plunged 59 feet down into the ravine in an unoccupied part of the Bronx Zoo, killing all seven inside, including three children.(AP Photo/Family Photo)

This undated photo provided by the family shows Jocelyn Gonzalez, 10, who died Sunday, April 29, 2012, when seven members of the same family, across three generations, died when their SUV plunged off a highway in to a ravine in the Bronx borough of New York. Police said at a briefing Monday that Maria Gonzalez, Jocelyn's mother, was driving at 68 mph when the vehicle bumped a concrete barrier on an overpass of the Bronx River Parkway, bounced across three lanes of traffic, jumped across a low concrete barrier and a guardrail, and plunged 59 feet down into the ravine in an unoccupied part of the Bronx Zoo, killing all seven inside, including three children. (AP Photo/Family Photo)

Police investigate the destroyed van that plunged over the Bronx River Parkway, Sunday April 29, 2012, in New York. Authorities say the out-of-control van plunged off a roadway near the Bronx Zoo, killing seven people, including three children. (AP Photo/ Louis Lanzano)

Skid marks and a scraped concrete barrier mark the spot where a van carrying seven occupants plunged off the highway to a wooded area below, Sunday April 29, 2012, in New York. Authorities say the out-of-control van plunged off a roadway near the Bronx Zoo, killing seven people, including three children. (AP Photo/ Louis Lanzano)

Seven candles are lit Monday, April 30, 2012, in the Bronx borough of New York, in a memorial to the seven family members who died the previous day in a horrifying when the SUV carrying three generations of family plunged more than 50 feet off a highway overpass and into a ravine on the grounds of the Bronx Zoo. The memorial, which includes photos of family members, was at the home on Taylor Ave., where the woman driving the van lived. (AP Photo/James Fitzgerald)

(AP) ? The section of highway where an accident sent seven members of a Bronx family flying over a guardrail and plummeting to their deaths has narrow lanes, steep hills, tight turns, inadequate guardrails and no breakdown lane, an auto safety group said Monday.

The Bronx River Parkway "lacks modern transportation engineering features," said Robert Sinclair, spokesman for the American Automobile Association's New York City affiliate. He said it was conceived in 1907 and opened in 1925 as "the first limited access multilane highway in the U.S."

Three sections of the parkway in the Bronx, including one at or near the accident site, are on the state Transportation Department's 5 Percent List, a federally mandated report of locations "exhibiting the most severe highway safety needs."

The driver, Maria Gonzalez, clipped a highway divider and damaged a tire Sunday afternoon before her SUV plunged off a highway and six stories down into a ravine on the grounds of the Bronx Zoo, killing three generations of a family, including three children, police said.

Juan Gonzalez, the driver's husband, blamed the state, at least in part, for the crash.

"He says it's very careless of the state to let that happen," a relative said, translating Gonzalez's Spanish at a funeral home. "There's been several incidents before this. Accidents such as this and they haven't done anything to prevent this."

The state Department of Transportation's only comment was an email message that said, "We are working closely with all agencies involved to determine the cause of this tragic accident."

On the highway, just before the accident site, is a sign that warns of "Limited Sight Distance" on the six-lane parkway, which runs north-south between the south Bronx and central Westchester County.

The accident was the second in the past year where a car fell off the same stretch of the parkway; the earlier accident wasn't fatal. In 2006, six people were killed on the parkway when one car crossed the median into oncoming traffic.

Police said Maria Gonzalez of the Bronx was driving south at 68 mph when she bumped a concrete barrier separating the north- and southbound lanes. With one tire damaged, her Honda Pilot skittered across three lanes of traffic, hit a 2-foot-high concrete curb and went airborne, clearing a 4-foot-tall guardrail.

"It is very strange that there is a curb there," Sinclair said. "You don't put curbs on high-speed roadways because they can serve as launching pads, which appears to be what happened here. A big Honda Pilot flew over a 4-foot guardrail."

He said the guardrail should be higher on an elevated roadway.

Gonzalez was driving well above the posted 50 mph limit, but speeding is common at that point and she may have been simply keeping up with traffic, said New York Police Department spokesman Paul Browne. He said there was no evidence Gonzalez was texting, on a phone or had been drinking. Toxicology tests are pending.

"There's no evidence of a mechanical failure," he added.

The medical examiner's office on Monday ruled the deaths accidental. Autopsies showed that all seven died from blunt force trauma.

The NYPD's accident investigation squad found "yaw marks" on the road, he said. He said they indicate a vehicle going perpendicular to traffic.

All the victims were wearing seat belts.

They were identified as Jacob Nunez, 85, and Ana Julia Martinez, 81, who were visiting from the Dominican Republic; their daughters, Gonzalez, 45, and Maria Nunez, 39, and three grandchildren. The children were Jocelyn Gonzalez, 10, the daughter of the driver, and Niely Rosario, 7, and Marly Rosario, 3, both daughters of Nunez.

At the Gonzalez home on Monday, a cousin of the women, Isabel Morel, said the grandparents' bodies were being returned to the Dominican Republic. A funeral for the mothers and their children is scheduled for Friday morning.

Two flower bouquets and seven tall religious candles lined the sidewalk near the stoop of the house. Photographs of Jocelyn and Marly sat behind a grate of a windowsill, one in pink overalls and white blouse, the other sporting a pixie haircut.

"This was supposed to be a time of great happiness," Morel said, adding that the SUV had just picked up the grandparents at Maria Nunez's home to take them to the Gonzalez home for a family party.

In the Dominican Republic community of Manuel Bueno, where the elderly couple lived, their son Antonio Nunez said, "The whole town is really sad."

He said several of his sisters had pooled their money to buy their parents' airline tickets.

Maria Nunez's husband, Juan Ramon Rosario, said he was working at a car wash when he learned of the tragedy.

"It's terrible for him and the whole family," said Andres Fulgencio, a cousin translating for the 34-year-old father of two. "Right now he can't think. He can't feel."

Juan Gonzalez, a livery cab driver, "feels destroyed," a translating relative said. Gonzalez said there was nothing wrong with the vehicle or his wife on Sunday morning.

"I never expected that we would go through a moment like this but we have to keep going," he said. He said he would have to work harder because his wife had just taken a maintenance job at Fordham University to help pay for their son's college education.

The wreck was the deadliest in New York City since the driver of a tour bus returning from a Connecticut casino in March 2011 lost control and slammed into a pole that sheared the bus nearly end to end, killing 14 passengers.

Relatives said a fund was being set up for donations toward funeral expenses. Fernando Mateo, president of the New York State Federation of Taxi Drivers, contributed $1,000 and said the costs could total $100,000.

___

Associated Press writers Verena Dobnik, Colleen Long and Claudia Torrens, videographer Bonny Ghosh and AP News Researcher Jennifer Farrar contributed to this report from New York. Associated Press writer Ezequiel Abiu Lopez contributed from Santo Domingo, Dominican Republic.

Associated Press

Storage Lubbock river cruises perth Hotels Lincoln City title loans in arizona

In India, Cheap Air Travel has Banished the Concept of it Being a ...

The advent of air travel has made life much easier than before. Don?t you agree? I think all of us should really thank the guy who first thought and conceptualised such a thing. We all know about the story of the man who first thought of this thing while looking at the birds and thinking of emulating them one day. He just kept looking at the wings of the birds and wished that he could fly sometime in the air, just like them. Tune back to today?s time when the concept of air travel is not at all new. It?s just another thing. Every kid in its senses runs after an airplane that he or she sees flying above his head but it?s not the same case when he grows up. It?s because he loses the urgency with which he feels and marvels at airplane. It?s not just specific to one person but to all.

Talking about India, air travel is a very new thing.

Not that the country did not have it for some time but because it was not easily available and more so affordable by all. Unlike today when a major class of flyers comes from the middle class, air travel was at one point of time considered to be a very luxurious deal. In earlier times when you said you had flown and come to a particular city, people assumed that you belonged to some wealthy family. In India, air travel was always considered to be associated with power and money. It was only the politicians and rich crowd that used to travel by air. But what has changed the mindset? The answer lies in the pricing of air travel now. The concept of cheap flights has made air travelling possible for all. You can now take cheap flights to Delhi, Mumbai and all other cities in the country. The numbers of flights that take off have also increased. People can easily take flights, Delhi to Mumbai, Kolkata, Chennai and every other city.

People who live in Delhi, the capital of the country India have now got all possible facilities to proudly call their city as one of the best air travel city. Whether for work purpose or for leisure if you go out, you have cheap flights to Delhi. This has made the task of people who have to go out for work easier as these flights help them save money and time both. Delhi and Mumbai for that matter have a lot of such people who keep shifting their base between the cities. In such a case, flights Delhi to Mumbai and vice versa help in cost cutting and experiencing luxury at the same time.?

Kiewit financial planner marketing origin energy rates Rocking Chairs for Kids

Avastin and Lucentis are equivalent in treating age-related macular degeneration

Avastin and Lucentis are equivalent in treating age-related macular degeneration [ Back to EurekAlert! ] Public release date: 30-Apr-2012
[ | E-mail | Share Share ]

Contact: Jean Horrigan
jh@nei.nih.gov
301-496-5248
NIH/National Eye Institute

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision were seen with monthly administration for this common, debilitating eye disease, according to researchers supported by the National Institutes of Health.

Of the two drugs, Avastin is most frequently used to treat AMD. However, prior to the Comparison of AMD Treatments Trials (CATT), a two-year clinical trial, the two drugs had never been compared head-to-head. Second year results were published today in the journal Ophthalmology. First year results were published in the May 19, 2011 issue of the New England Journal of Medicine.

AMD is the leading cause of vision loss and blindness in older Americans. In its advanced stages, the wet form of AMD spurs the growth of abnormal blood vessels, which leak fluid and blood into the macula and obscure vision. The macula is the central portion of the retina that allows us to look straight ahead and to perceive fine visual detail. Accumulation of fluid and blood damages the macula, causing loss of central vision, which can severely impede mobility and independence. Without treatment, most patients become unable to drive, read, recognize faces or perform tasks that require hand-eye coordination.

"Therapies for AMD require repeated treatment to prevent vision loss. Results of this clinical trial provide evidence that long-term treatment with either drug results in a robust and lasting improvement in vision. Patients and clinicians now have valuable information to base treatment decisions," said Paul A. Sieving, M.D., Ph.D., director of the NEI.

Avastin and Lucentis block growth of abnormal blood vessels and leakage of fluid from the vessels. Lucentis was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of AMD. Avastin is very similar to Lucentis but is not approved by the FDA for this purpose. Avastin is approved for other indications. Most clinicians use these drugs on an as-needed basis when there is evidence of active disease, such as fluid leakage. However, in the original clinical trials for AMD, Lucentis was administered monthly. It was unknown if as-needed dosing would produce the same long-term visual improvements achieved with monthly administration.

Thus, CATT was designed to compare Avastin and Lucentis with monthly and as-needed treatment schedules. At enrollment, patients were assigned to four treatment groups defined by drug (Avastin or Lucentis) and dosing regimen (monthly or as-needed). After year one, patients initially assigned to monthly treatment were randomly reassigned to monthly or as-needed treatment without changing their drug assignment.

At two years, visual acuity with monthly treatment was slightly better than with as-needed dosing, regardless of the drug. As measured on an eye chart, monthly treatment resulted in a mean improvement of about half a line better than as-needed dosing. Switching to as-needed treatment after one year of monthly treatment yielded outcomes nearly equal to those obtained with as-needed treatment for the full two years. Changes in retinal anatomy differed by drug and frequency of treatment, but did not have an impact on vision through two years.

"Both drugs were highly effective regardless of the approach to dosing. There was slightly less vision gain with as-needed treatment. Patients seeking the small extra advantage of monthly treatment need to be mindful of the additional burden, risks, and costs of monthly injections. Since as-needed dosing required 10 fewer eye injections over the course of two years and yielded similar visual results, many patients may choose this option." said Daniel F. Martin, M.D., study chair for CATT and chairman of the Cole Eye Institute at the Cleveland Clinic.

Adverse events indicate development or worsening of a medical condition. They may or may not be causally associated with the clinical trial treatment, but they are always monitored and reported in any clinical trial. The median age of patients in CATT was over 80 years, and a high rate of hospitalizations would be anticipated as a result of chronic or acute medical conditions more common to older populations.

Serious adverse events (SAEs) occurred at a 40 percent rate for patients receiving Avastin and a 32 percent rate for patients receiving Lucentis. Although Avastin had a higher rate of SAEs, they were distributed across many different conditions, most of which were not associated with Avastin when evaluated in cancer clinical trials, in which the drug was administered at 500 times the dose used for AMD. Fewer doses were associated with a higher rate of SAEs, which is not a typical dose-response relationship. The number of deaths, heart attacks, and strokes were low and similar for both drugs during the study. CATT was not capable of determining whether there is an association between a particular adverse event and treatment. Additional data from other clinical trials may provide information on long-term safety profiles of these drugs when used to treat AMD.

"The dramatic and lasting improvement in vision with these two drugs is extraordinary. At two-years, two-thirds of patients had driving vision (20/40 vision or better). With previous treatments, only 15 percent of patients retained similar visual acuity," said Maureen Maguire, Ph.D., principal investigator, CATT Coordinating Center at the University of Pennsylvania.

###

Find more information about this clinical trial (NCT00593450) at http://clinicaltrials.gov

Supporting NIH Grants: U10EY017823, U10EY017828, U10EY017825

For more information and audiovisual materials, visit http://www.nei.nih.gov/catt/

The National Eye Institute, part of the National Institutes of Health, leads the federal government's research on the visual system and eye diseases. NEI supports basic and clinical science programs that result in the development of sight-saving treatments. For more information, visit www.nei.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Avastin and Lucentis are equivalent in treating age-related macular degeneration [ Back to EurekAlert! ] Public release date: 30-Apr-2012
[ | E-mail | Share Share ]

Contact: Jean Horrigan
jh@nei.nih.gov
301-496-5248
NIH/National Eye Institute

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision were seen with monthly administration for this common, debilitating eye disease, according to researchers supported by the National Institutes of Health.

Of the two drugs, Avastin is most frequently used to treat AMD. However, prior to the Comparison of AMD Treatments Trials (CATT), a two-year clinical trial, the two drugs had never been compared head-to-head. Second year results were published today in the journal Ophthalmology. First year results were published in the May 19, 2011 issue of the New England Journal of Medicine.

AMD is the leading cause of vision loss and blindness in older Americans. In its advanced stages, the wet form of AMD spurs the growth of abnormal blood vessels, which leak fluid and blood into the macula and obscure vision. The macula is the central portion of the retina that allows us to look straight ahead and to perceive fine visual detail. Accumulation of fluid and blood damages the macula, causing loss of central vision, which can severely impede mobility and independence. Without treatment, most patients become unable to drive, read, recognize faces or perform tasks that require hand-eye coordination.

"Therapies for AMD require repeated treatment to prevent vision loss. Results of this clinical trial provide evidence that long-term treatment with either drug results in a robust and lasting improvement in vision. Patients and clinicians now have valuable information to base treatment decisions," said Paul A. Sieving, M.D., Ph.D., director of the NEI.

Avastin and Lucentis block growth of abnormal blood vessels and leakage of fluid from the vessels. Lucentis was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of AMD. Avastin is very similar to Lucentis but is not approved by the FDA for this purpose. Avastin is approved for other indications. Most clinicians use these drugs on an as-needed basis when there is evidence of active disease, such as fluid leakage. However, in the original clinical trials for AMD, Lucentis was administered monthly. It was unknown if as-needed dosing would produce the same long-term visual improvements achieved with monthly administration.

Thus, CATT was designed to compare Avastin and Lucentis with monthly and as-needed treatment schedules. At enrollment, patients were assigned to four treatment groups defined by drug (Avastin or Lucentis) and dosing regimen (monthly or as-needed). After year one, patients initially assigned to monthly treatment were randomly reassigned to monthly or as-needed treatment without changing their drug assignment.

At two years, visual acuity with monthly treatment was slightly better than with as-needed dosing, regardless of the drug. As measured on an eye chart, monthly treatment resulted in a mean improvement of about half a line better than as-needed dosing. Switching to as-needed treatment after one year of monthly treatment yielded outcomes nearly equal to those obtained with as-needed treatment for the full two years. Changes in retinal anatomy differed by drug and frequency of treatment, but did not have an impact on vision through two years.

"Both drugs were highly effective regardless of the approach to dosing. There was slightly less vision gain with as-needed treatment. Patients seeking the small extra advantage of monthly treatment need to be mindful of the additional burden, risks, and costs of monthly injections. Since as-needed dosing required 10 fewer eye injections over the course of two years and yielded similar visual results, many patients may choose this option." said Daniel F. Martin, M.D., study chair for CATT and chairman of the Cole Eye Institute at the Cleveland Clinic.

Adverse events indicate development or worsening of a medical condition. They may or may not be causally associated with the clinical trial treatment, but they are always monitored and reported in any clinical trial. The median age of patients in CATT was over 80 years, and a high rate of hospitalizations would be anticipated as a result of chronic or acute medical conditions more common to older populations.

Serious adverse events (SAEs) occurred at a 40 percent rate for patients receiving Avastin and a 32 percent rate for patients receiving Lucentis. Although Avastin had a higher rate of SAEs, they were distributed across many different conditions, most of which were not associated with Avastin when evaluated in cancer clinical trials, in which the drug was administered at 500 times the dose used for AMD. Fewer doses were associated with a higher rate of SAEs, which is not a typical dose-response relationship. The number of deaths, heart attacks, and strokes were low and similar for both drugs during the study. CATT was not capable of determining whether there is an association between a particular adverse event and treatment. Additional data from other clinical trials may provide information on long-term safety profiles of these drugs when used to treat AMD.

"The dramatic and lasting improvement in vision with these two drugs is extraordinary. At two-years, two-thirds of patients had driving vision (20/40 vision or better). With previous treatments, only 15 percent of patients retained similar visual acuity," said Maureen Maguire, Ph.D., principal investigator, CATT Coordinating Center at the University of Pennsylvania.

###

Find more information about this clinical trial (NCT00593450) at http://clinicaltrials.gov

Supporting NIH Grants: U10EY017823, U10EY017828, U10EY017825

For more information and audiovisual materials, visit http://www.nei.nih.gov/catt/

The National Eye Institute, part of the National Institutes of Health, leads the federal government's research on the visual system and eye diseases. NEI supports basic and clinical science programs that result in the development of sight-saving treatments. For more information, visit www.nei.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


chain link fence Sacramento LED Lighting Fixtures shipping to united arab emirates from usa private certifiers sydney

THE BEST supplements youre NOT using! Dont miss this?.? | Health ...

I spent the day learning from 4 of North Americas foremost authorities on sports?nutrition and performance at the ISSN seminar in Orlando, Florida today.

?Events like this show their enormous value in the fact that EVERY conclusion presented?is direct result of professionally run, doctor supervised studies. ?NO BS bro-science here!

The take-home messages from today were incredible, and applicable IMMEDIATELY to?YOUR training AND mine!

A lot of the seminar was based around pre workout, peri workout and post workout?nutrition.

PRE-WORKOUT

-one of the points that every presenter wanted to drive home was something that?everyone reading this email already knows, because I ask it before ever giving an answer?to a question......

WHAT IS YOUR GOAL?First and foremost it is necessary to determine what exactly youre trying to do. Each?person is different, has different goals, and have different chemistry.

The general consensus about what supplements should be taken pre workout seem to?be HMB, glycocarn, BCAA (or EAA), creatine and possibly a carb (which, as is explained??in MI40, is dependent on your goals, as well as your "limiting factor").
PERI WORKOUT(DURING WORKOUT)

The primary focus was on reducing what is termed "oxidative stress". Basically the?stress resulting from an increased oxygen consumption that occurs from intense?exercise.

It was said that the best ways to reduce oxidative stress(also known as "the ageing?process") was to supplement with Vitamins C, E, and selenium.

Alpha lipoic acid, and SOD were also mentioned as being large contributors to minimizing??the harmful effects of exercise.

Dosages are dependent on size of the individual and the amount of stress placed on the?body during exercise.

POST WORKOUTIt is well known that post workout nutrition is THE number one most important factor?in improved performance and muscle growth.

It is IMPERATIVE to halt the catabolic processes initiated by exercise immediately with?a carbohydrate supplement and amino acids or protein supplement. (hydrolyzed whey or?whey isolate like ISO-FLEX are proven to be best).

It was said that the most important things to be consuming post workout are obviously?carbs, Branch Chain Aminos, and glycocarn, and creatine monohydrate (still proven to?be the best type of creatine)I added my own twist to this post workout nutrition segment with something I learned?very recently about GREENS being the number one way to increase NO2 production?in the body (oh ya, it was also proven to be common knowledge the Arginine has NO?effect on this).

These type of conferences prove very valuable because they help to completely?dispel all the BS that we are bombarded with on a daily basis about new fads and?the next revolutionary product.

The truth is, basics are basics for a reason and no one is really creating anything new...?atleast not yet!

Supplements with a positive review:Whey isolate

Creatine (shown to have no negative effects)

BCAA

HMB acid

caffeine (not coffee)

LEUCINE (yes this is bold, so take notice!)

Omega 3

Greens(Bens addition ;))

I wish everyone 10lbs of NEW MUSCLE GROWTH!!

BOOM!

BPak

discount merchandise seopartner review Criminal Drug Defense Attorneys Phoenix akadema gloves